Abstract
Background The perturbation of tryptophan (TRP)-kynurenine (KYN) metabolism has been linked with HIV infection and cardiovascular disease (CVD), but the interrelationship among TRP metabolites, gut microbiota, and atherosclerosis has not yet been fully understood in the context of HIV infection.
Methods We included 361 women (241 HIV+, 120 HIV-) with carotid artery plaque assessments from the Women’s Interagency HIV Study, measured ten plasma TRP metabolites and profiled fecal gut microbiome. TRP metabolites related gut microbial features were selected through the Analysis of Compositions of Microbiomes with Bias Correction method. The associations of TRP metabolites and related microbial features with plaque were examined using multivariable logistic regression.
Results While plasma kynurenic acid (KYNA) (odds ratio [OR]=1.93[1.12, 3.32] per one SD increase, P=0.02) and KYNA/TRP (OR=1.83[1.08, 3.09], P=0.02) were positively associated with plaque, indole-3-propionate (IPA) (OR=0.62 [0.40, 0.98], P=0.03) and IPA/KYNA (OR=0.51[0.33, 0.80], P<0.01) were inversely associated with plaque. Five gut bacterial genera and many affiliated species were positively associated with IPA (FDR-q<0.25), including Roseburia sp., Eubacterium sp., Lachnospira sp., and Coprobacter sp.; but no bacterial genera were found to be associated with KYNA. Furthermore, an IPA-associated-bacteria score was inversely associated with plaque (OR=0.47[0.28, 0.79], P<0.01). But no significant effect modification by HIV serostatus was observed in these associations.
Conclusions In a cohort of women living with and without HIV infection, plasma IPA levels and related gut bacteria were inversely associated with carotid artery plaque, suggesting a potential beneficial role of IPA and its gut bacterial producers in atherosclerosis and CVD.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the National Heart, Lung, and Blood Institute (NHLBI) R01HL140976. Other related funding sources included K01HL129892, K01HL137557, R01HL126543, R01 HL132794, R01HL083760 and R01HL095140 from the NHLBI, R01MD011389 from the National Institute on Minority Health and Health Disparities, U01 AI035004 and the Einstein-Rockefeller-CUNY Center for AIDS Research (P30AI124414) funded by the National Institute of Allergy and Infectious Diseases, Einstein Cancer Research Center (P30CA013330) funded by National Cancer Institute, and the Feldstein Medical Foundation Research Grant to Q.Q.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants provided written informed content and the present study was reviewed and approved by the Institutional Review Board (IRB) at Albert Einstein College of Medicine (IRB no: 2018-9386).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Any requests as to the potential replication or source data should be addressed to the corresponding author.
Abbreviations
- HIV
- human immunodeficiency virus
- WIHS
- Women’s Interagency HIV Study
- MACS
- Multicenter AIDS Cohort Study
- (MWCCS)
- MACS-WIHS Combined Cohort Study
- CVD
- cardiovascular disease
- FDR
- false discovery rate
- TRP
- tryptophan
- KYN
- kynurenine
- KYNA
- kynurenic acid
- ILA
- indole-3-lactic acid
- IAA
- indole-3-acid-acetic
- IPA
- indole-3-propionic acid
- HILIC
- Hydrophilic Interaction Liquid Chromatography
- MS
- Mass Spectrometry
- SHOGUN
- shallow-shotgun
- IQR
- inter-quartile range
- SD
- standard deviation
- ANCOMBC
- Analysis of Compositions of Microbiomes with Bias Correction
- (KOs)
- KEGG Ortholog groups
- CLR
- central log ratio
- Cs-FLDA
- 3-(aryl) acryloyl-CoA:(R)-3-(aryl) lactate CoA-transferase
- ACDS
- butyryl-CoA dehydrogenase
- OR
- odds ratio
- ART
- antiretroviral therapy
- BMI
- body mass index
- TC
- total cholesterol
- HDL
- high-density lipoprotein
- SBP
- systolic blood pressure
